Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Lennart Poser

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Frontiers in Artificial Intelligence|March 2, 2026
Improving reliability and accuracy of structured data extraction using a consensus large-language model approach-a use case description in multiple sclerosisPhilip Lennart Poser, Rafael Klimas, Justus Luerweg, et al.
Der Nervenarzt|April 12, 2023
[Over one year of B‑cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study]Rafael Klimas, Anna-Sophia Karl, Philip Lennart Poser, et al.
Journal of Neurology|July 22, 2024
Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational studyAnna-Sophia Karl, Rafael Klimas, Melina Katsimpoura, et al.
European Journal of Neurology|August 4, 2023
Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathyPhilip Lennart Poser, Gulchan Shazadi Sajid, Léon Beyer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 2026
Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohortPhilip Lennart Poser, Barbara Gisevius, Marianne Tokic, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Frontiers in Artificial Intelligence|March 2, 2026
Improving reliability and accuracy of structured data extraction using a consensus large-language model approach-a use case description in multiple sclerosisPhilip Lennart Poser, Rafael Klimas, Justus Luerweg, et al.
Der Nervenarzt|April 12, 2023
[Over one year of B‑cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study]Rafael Klimas, Anna-Sophia Karl, Philip Lennart Poser, et al.
Journal of Neurology|July 22, 2024
Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational studyAnna-Sophia Karl, Rafael Klimas, Melina Katsimpoura, et al.
European Journal of Neurology|August 4, 2023
Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathyPhilip Lennart Poser, Gulchan Shazadi Sajid, Léon Beyer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 2026
Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohortPhilip Lennart Poser, Barbara Gisevius, Marianne Tokic, et al.
Pageof 1